Mostrando 10 resultados de: 10
Filtros aplicados
Publisher
British Journal of Clinical Pharmacology(2)
European Journal of Clinical Pharmacology(2)
Therapeutic Drug Monitoring(2)
Clinical Pharmacology & Therapeutics(1)
Clinical Pharmacology and Therapeutics(1)
Área temáticas
Farmacología y terapéutica(10)
Enfermedades(4)
Bioquímica(2)
Ginecología, obstetricia, pediatría, geriatría(2)
Fisiología humana(1)
Origen
scopus(10)
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
ArticleAbstract: In a previous study we showed that the disposition of clozapine after a single oral dose is unrelatePalabras claves:Autores:Adrián LLerena, Alm C., Benitez Rodriguez J., Bertilsson L., Bondesson U., Carrillo J., Dahl M.L., Lindstrom L., Ramos S., Rodriguez de la Rubia I.Fuentes:scopusDebrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents
ArticleAbstract: Debrisoquin and S‐mephenytoin hydroxylation phenotypes were determined in 72 Spanish psychiatric patPalabras claves:Autores:Adrián LLerena, Cobaleda J., Dahl M.L., Herraiz A., Johansson I.Fuentes:scopusCYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
ArticleAbstract: Objective: This study analyzed the frequency of CYP2C9 variant alleles and evaluated the impact of CPalabras claves:CYP2C9, Diclofenac, GenotypingAutores:Adrián LLerena, Berecz R., Dahl M.L., Dorado P., Norberto M., Yasar U.Fuentes:scopusGenetic factors in the metabolism of haloperidol.
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusDisposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.
ArticleAbstract: A large interindividual variability has previously been demonstrated in the bioavailability, steady‐Palabras claves:Autores:Adrián LLerena, Bertilsson L., Bondesson U., Dahl M.L., Lindstrom L.Fuentes:scopusDisposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.
ReviewAbstract:Palabras claves:Autores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on debrisoquine hydroxylation phenotype
ArticleAbstract: To investigate the importance of genetic factors for the regulation of haloperidol metabolism, we stPalabras claves:debrisoquine, Haloperidol, humans, pharmacogeneticsAutores:Adrián LLerena, Alm C., Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
ArticleAbstract: We have previously shown that the disposition of haloperidol is decreased in poor (PM) compared to ePalabras claves:debrisoquine, humans, pharmacogenetics, Reduced haloperidolAutores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusPharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype
ArticleAbstract: Background and aim: Losartan is metabolized by polymorphic CYP2C9 to E-3174. Our aim was to evaluatePalabras claves:Autores:Adrián LLerena, Dahl M.L., Dorado P., Eliasson E., Forslund-Bergengren C., Sjoqvist F., Tybring G., Yasar U.Fuentes:scopusThioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
ArticleAbstract: Background: Approximately 7% of Caucasians have genetically impaired activity of the cytochrome P450Palabras claves:Cytochrome p450, pharmacogenetics, smoking, ThioridazineAutores:Adrián LLerena, Berecz R., Dahl M.L., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopus